These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29579214)

  • 1. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.
    Miranda Bastos AC; Vandecasteele SJ; Spinewine A; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2018 Jun; 73(6):1630-1638. PubMed ID: 29579214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of Temocillin.
    Alexandre K; Fantin B
    Clin Pharmacokinet; 2018 Mar; 57(3):287-296. PubMed ID: 28849402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and dosing simulations of total and unbound temocillin in the plasma and CSF of neurocritically ill patients with external ventricular drain-related cerebral ventriculitis.
    Ngougni Pokem P; Liu X; Parker SL; Verroken A; Collienne C; Finet P; Wijnant GJ; Laterre PF; Roberts JA; Van Bambeke F; Wittebole X
    J Antimicrob Chemother; 2024 Feb; 79(2):429-442. PubMed ID: 38153240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients.
    Vandecasteele SJ; Miranda Bastos AC; Capron A; Spinewine A; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2015 Dec; 46(6):660-5. PubMed ID: 26603304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.
    Layios N; Visée C; Mistretta V; Denooz R; Maes N; Descy J; Frippiat F; Marchand S; Grégoire N
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205221. PubMed ID: 35099273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing vancomycin dosage regimens in relation to high-flux haemodialysis.
    Hui K; Patel K; Nalder M; Nelson C; Buising K; Pedagogos E; Kong DCM; Kirkpatrick CMJ
    J Antimicrob Chemother; 2019 Jan; 74(1):130-134. PubMed ID: 30215721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
    Chung EK; Fleming MR; Cheatham SC; Kays MB
    Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E).
    Namiki T; Yokoyama Y; Hashi H; Oda R; Jibiki A; Kawazoe H; Matsumoto K; Suzuki S; Nakamura T
    Pharmacotherapy; 2024 Feb; 44(2):149-162. PubMed ID: 37984818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacological target attainment of standard temocillin dosing in non-critically ill patients with complicated urinary tract infections.
    Wijnant GJ; Ngougni Pokem P; Coessens M; Cottone E; Ermtraud J; Goeman L; Vervaeke S; Wicha SG; Van Bambeke F
    J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38985543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
    Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
    Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
    Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.